AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma Academic Article uri icon

Overview

MeSH Major

  • Drug Resistance, Neoplasm
  • Lymphoma, Large B-Cell, Diffuse
  • Proto-Oncogene Proteins c-bcl-2
  • Proto-Oncogene Proteins c-bcl-6

abstract

  • Lenalidomide improved efficacy of rituximab in patients with recurrent indolent lymphoma, with an acceptable safety profile.

publication date

  • May 10, 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.19.00010

PubMed ID

  • 30897038

Additional Document Info

start page

  • 1188

end page

  • 1199

volume

  • 37

number

  • 14